Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat.
about
Evidence for neurogenesis in the adult mammalian substantia nigra.Modeling Parkinson's disease in the common marmoset (Callithrix jacchus): overview of models, methods, and animal careAnimal models of multiple system atrophyThe transfection of BDNF to dopamine neurons potentiates the effect of dopamine D3 receptor agonist recovering the striatal innervation, dendritic spines and motor behavior in an aged rat model of Parkinson's diseaseElevated homocysteine by levodopa is detrimental to neurogenesis in parkinsonian modelReduced vocal variability in a zebra finch model of dopamine depletion: implications for Parkinson disease.Behavioral and neurophysiological correlates of striatal dopamine depletion: a rodent model of Parkinson's disease.Differential sensitivity of cranial and limb motor function to nigrostriatal dopamine depletion.Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's diseaseSensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease.Differential effects of intrastriatal 6-hydroxydopamine on cell number and morphology in midbrain dopaminergic subregions of the ratPharmacogenetic stimulation of cholinergic pedunculopontine neurons reverses motor deficits in a rat model of Parkinson's diseaseDelayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease.Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson's disease.Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transferComparison of unilateral and bilateral intrastriatal 6-hydroxydopamine-induced axon terminal lesions: evidence for interhemispheric functional coupling of the two nigrostriatal pathways.The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson's disease.Feasibility and Efficacy of Intra-Arterial Administration of Mesenchymal Stem Cells in an Animal Model of Double Toxin-Induced Multiple System Atrophy.How Accurate Appraisal of Behavioral Costs and Benefits Guides Adaptive Pain Coping.Gene therapy in the CNS.Neurturin protects against 6-hydroxydopamine-induced reductions in evoked dopamine overflow in rat striatum.Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulationGenetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging.T-Lymphocyte Deficiency Exacerbates Behavioral Deficits in the 6-OHDA Unilateral Lesion Rat Model for Parkinson's Disease.Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's diseaseQuantitative assessment of gait and neurochemical correlation in a classical murine model of Parkinson's disease.Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson diseaseA novel neuroprotective therapy for Parkinson's disease using a viral noncoding RNA that protects mitochondrial complex I activity.Rutin protects dopaminergic neurons from oxidative stress in an animal model of Parkinson's disease.Targeting caspase-3 as dual therapeutic benefits by RNAi facilitating brain-targeted nanoparticles in a rat model of Parkinson's disease.Neuroprotective activity of peripherally administered liver growth factor in a rat model of Parkinson's diseaseFunctional neuroprotection and efficient regulation of GDNF using destabilizing domains in a rodent model of Parkinson's disease.Activation of GSK-3β and caspase-3 occurs in Nigral dopamine neurons during the development of apoptosis activated by a striatal injection of 6-hydroxydopamineDown-regulation of microglial activity attenuates axotomized nigral dopaminergic neuronal cell loss.Noradrenaline and Parkinson's disease.Expression of endogenous Mkp1 in 6-OHDA rat models of Parkinson's disease.Within-session analysis of amphetamine-elicited rotation behavior reveals differences between young adult and middle-aged F344/BN rats with partial unilateral striatal dopamine depletionDopaminergic-like neurons derived from oral mucosa stem cells by developmental cues improve symptoms in the hemi-parkinsonian rat modelAndrogens exacerbate motor asymmetry in male rats with unilateral 6-hydroxydopamine lesion.Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.
P2860
Q24669979-ADF6E3D1-CC76-430B-AF06-C279D932D3A5Q26772285-D475DA2C-F289-4C75-92D4-C21F95D64DCEQ27015535-8ADB773E-9A5A-41B2-901B-61066ABA3359Q27316252-43B23069-6885-428B-A6F0-1052BAF52381Q27334004-13EB2448-1C1B-4BEB-AAD9-B4AE5B303992Q28606556-547D3FC9-795C-4EFF-B70D-E867A6DCD135Q30395768-DE297C6E-FD1B-4AEF-B862-8F1C50FCF9F1Q30444369-4F60C5DC-6D06-4BC1-91A4-0F684FF4EC2BQ30493158-CFD9259F-8F39-4292-8A07-CA220DE01DAAQ30512976-80130C06-2D63-4FC1-8932-D48393A89997Q30585312-70A269F3-BAE5-4031-B136-1846D9D163D4Q30665304-780B4423-C1C8-4460-940C-D977A7EE5469Q30666545-5798E6E5-47EB-4430-9A41-18B2345119E1Q30829115-F04E7BE4-FD9A-4C6D-9396-9B677FC57F1AQ31045537-D11424DA-EB40-426F-AB9D-FCF45FF09DECQ32160990-5D06D522-254F-41F1-9201-BF8F11D91870Q33656315-B3765B0D-EC7D-44D3-8627-2DBC6CD3FB72Q33722037-BD1AC9F8-835C-400D-9C9E-63FB30A865C4Q33785851-DC4AFCE1-93A6-4A46-B10C-6D56F1C664C5Q33837123-A3524816-5432-42FE-AF52-991413B07DD1Q34108184-6274B78B-4C3F-48FC-BFCC-9CE2C2BDEB4CQ34223052-39404C56-F585-4D07-88F2-F7227C90BA18Q34325540-E1ADF1FA-057C-443B-BA6C-9998E539BCF8Q34392867-EA1E7C5B-C7EB-488E-820F-923E5C205261Q34473323-E54FADFB-0CF9-4F29-9BB1-B4B86034D134Q34476803-6CA65F04-91E3-460D-8ACF-39A5909A62FDQ34591684-D5A87016-25D2-4C38-94E1-0183258C9D75Q34634457-44A6BFB8-F623-4FBB-8043-4B44264B6C9DQ34634606-7D2CEBE1-CC19-47ED-9145-94C9D79C9A80Q34722724-BA72F06B-A562-469F-9FF1-1F4C2A29685EQ34826133-D9EC5698-346E-4709-9BAC-27F2CC879D6FQ34861724-3CCC2BB4-CB40-4CD2-8748-1F499CC0C17EQ34936413-E282D658-3A56-428B-8A0F-6B7E996E6F9AQ35007941-8F5CAB3E-B9E9-4102-B92D-E87A32D0B617Q35013240-4437EAC1-984D-4129-B64F-C89EE05C2770Q35168296-97E3DECF-1654-4454-B21C-77796EB62B70Q35190293-52805E63-CA71-4834-BF58-52C5FCD6093FQ35191399-B0575A9F-0B27-4E20-820A-98174BBBFE7AQ35534149-2AA33B1A-EC6F-4ADE-8836-589251BE963AQ35589979-A7382FC4-3AEF-4C23-BD32-93B238346912
P2860
Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Characterization of behavioral ...... 6-hydroxydopamine in the rat.
@en
Characterization of behavioral ...... 6-hydroxydopamine in the rat.
@nl
type
label
Characterization of behavioral ...... 6-hydroxydopamine in the rat.
@en
Characterization of behavioral ...... 6-hydroxydopamine in the rat.
@nl
prefLabel
Characterization of behavioral ...... 6-hydroxydopamine in the rat.
@en
Characterization of behavioral ...... 6-hydroxydopamine in the rat.
@nl
P356
P1476
Characterization of behavioral ...... 6-hydroxydopamine in the rat.
@en
P2093
P304
P356
10.1006/EXNR.1998.6848
P407
P577
1998-08-01T00:00:00Z